2.05

1.91% -0.04

After Hours: 2.05

Indaptus Therapeutics Inc (INDP)

Overview News Price History Financials Discussions Forecast

Indaptus Therapeutics Inc stock is traded at $2.05, with a volume of 31,425. It is down -1.91% in the last 24 hours and up +17.14% over the past month. Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Previous Close:

$2.09

Open:

$2.05

24h Volume:

31,425

Relative Volume:

0.71

Market Cap:

$4.60M

Revenue:

Net Income/Loss:

$-20.85M

P/E Ratio:

-0.127

EPS:

-16.1435

Net Cash Flow:

$-15.72M

1W Performance:

-29.79%

1M Performance:

+17.14%

6M Performance:

-23.51%

1Y Performance:

+376.74%

1-Day Range:

$2.03

$2.1951

1-Week Range:

$2.00

$3.09

52-Week Range:

$0.2701

$13.40

Indaptus Therapeutics Inc Stock (INDP) Company Profile

Name

Indaptus Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(646) 427-2727

Address

3 COLUMBUS CIRCLE, NEW YORK

Employee

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

INDP's Discussions on Twitter

Compare INDP vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INDP Indaptus Therapeutics Inc	2.05	4.69M	0	-20.85M	-15.72M	-16.14
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Indaptus Therapeutics Inc Stock (INDP) Latest News

May 04, 2026

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

May 04, 2026

Apr 29, 2026

Large holders in Indaptus (INDP) revise stakes and end group status - Stock Titan

Apr 29, 2026

Apr 27, 2026

Indaptus Therapeutics (INDP) Stock: Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenue - Newser

Apr 27, 2026

Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenueVerified Stock Signals - Newser

Apr 27, 2026

Apr 25, 2026

Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Amendment Reflects Legal Name Change - Minichart

Apr 25, 2026

Apr 24, 2026

Indaptus Therapeutics (INDP) refreshes board with two independents as one resigns - Stock Titan

Apr 24, 2026

Apr 23, 2026

Indaptus Therapeutics (INDP) reshapes board with two new independents and one exit - Stock Titan

Apr 23, 2026

Indaptus Therapeutics Adds Independent Directors Amid Board Refresh - TipRanks

Apr 23, 2026

Indaptus Therapeutics appoints two new independent directors and announces board changes By Investing.com - Investing.com South Africa

Apr 23, 2026

Indaptus Therapeutics appoints two new independent directors and announces board changes - Investing.com

Apr 23, 2026

Indaptus Therapeutics names Tim Ruan and Yi Zhang as independent directors; Matthew McMurdo resigns - TradingView

Apr 23, 2026

Apr 20, 2026

Indaptus (INDP) director Lu Qinglai submits initial Form 3 ownership - Stock Titan

Apr 20, 2026

Is Indaptus Therapeutics (INDP) stock trading at a premium valuation (Momentum Building) 2026-04-20Buy Signals - Newser

Apr 20, 2026

Apr 18, 2026

Indaptus Therapeutics (INDP) Stock: Why Automation Investment (Soars) 2026-04-18Trend Analysis - Xã Thanh Hà

Apr 18, 2026

Apr 17, 2026

Momentum Shift: Should I hold or sell Indaptus Therapeutics Inc nowInflation Watch & Daily Stock Trend Watchlist - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Published on: 2026-04-13 10:12:55 - baoquankhu1.vn

Apr 12, 2026

Apr 06, 2026

[SCHEDULE 13G/A] Indaptus Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan

Apr 06, 2026

Risk Off: Why is Indaptus Therapeutics Inc stock going up2026 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn

Apr 06, 2026

Will Indaptus Therapeutics (INDP) Stock Outperform S&P 500 | Price at $1.54, Down 3.75%Stock Accumulation - Newser

Apr 06, 2026

Apr 05, 2026

Indaptus Therapeutics Appoints Yu Ding as New Chief Financial Officer Effective April 2026 - Minichart

Apr 05, 2026

Apr 04, 2026

Indaptus Therapeutics Names New CFO, Refreshes Board Oversight - The Globe and Mail

Apr 04, 2026

Apr 03, 2026

Indaptus Therapeutics announces CFO transition and new board appointment - Investing.com

Apr 03, 2026

INDP Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 03, 2026

Indaptus Therapeutics announces CFO transition and new board appointment By Investing.com - Investing.com South Africa

Apr 03, 2026

Indaptus appoints Yu Ding as CFO; Nir Sassi resigns - TradingView — Track All Markets

Apr 03, 2026

Indaptus Therapeutics (INDP) names new CFO and independent director - Stock Titan

Apr 03, 2026

Apr 02, 2026